Peter Libby MDMallinckrodt Professor of Medicine, Harvard Medical School; Cardiovascular Specialist, Brigham and Women’s Hospital, Boston, Massachusetts
Dr. Libby received his medical degree from the University of California, San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital (now Brigham and Women’s Hospital) in Boston, Massachusetts. He also holds an honorary Master of Arts degree from Harvard University, Cambridge, Massachusetts, and honorary doctorates from the University of Lille, France, and from Laval University in Québec Canada. He served as the Chief of Cardiovascular Medicine at Brigham and Women’s Hospital from 1998 through 2014. He is currently the Mallinckrodt Professor of Medicine at Harvard Medical School in Boston, Massachusetts.
Dr. Libby has received numerous awards and recognitions for his research accomplishments including the Gold Medal of the European Society of Cardiology and the Basic Research Prize of the American Heart Association in 2011; the Anitschkow Prize in Atherosclerosis Research of the European Atherosclerosis Society in 2013; the Special Award of the Heart Failure Association of the European Society of Cardiology in 2014; the Ernst Jung Gold Medal for Medicine for 2016; and the Earl Benditt Award of the North American Vascular Biology Organization in 2017. In 2018 he received the Arthur S. Agatston Cardiovascular Disease Prevention Award from the Society of Cardiovascular Computed Tomography. He received the Honorary Award for the Lecture on Clinical Science from the German Cardiac Society in 2019. He has garnered a number of lifetime achievement awards from various organizations and has delivered over 150 named or keynote lectures worldwide.
His areas of clinical expertise include general and preventive cardiology. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has a particular devotion to translate laboratory studies to pilot and then large-scale clinical cardiovascular outcome trials.
He has published extensively in medical journals, including Circulation and The New England Journal of Medicine, among others. He is also active in many organizations, including the American College of Cardiology and the American Heart Association, and was elected to the American Society for Clinical Investigation, the Association of American Physicians, and the Association of University Cardiologists, where he served as President.
Dr. Libby is an unpaid consultant to, or involved in clinical trials for:
Amgen, AstraZeneca, Esperion Therapeutics, Ionis Pharmaceuticals, Kowa Pharmaceuticals, Novartis, Pfizer, Sanofi-Regeneron, and XBiotech, Inc.
Dr. Libby is a member of scientific advisory board for:
Amgen, Corvidia Therapeutics, DalCor Pharmaceuticals, IFM Therapeutics, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, and XBiotech, Inc.
Dr. Libby’s laboratory has received research funding in the last 2 years from Novartis.
Recent Contributions to PracticeUpdate:
- Colchicine in Patients With Chronic Coronary Disease
- Vupanorsen Lowers Triglycerides and Atherogenic Lipoproteins in Patients With Diabetes, Hepatic Steatosis, and Hypertriglyceridemia
- LDL-C Concentration <70 mg/dL and Carotid Atherosclerosis
- Lipoprotein(a) Reduction in Individuals With CVD
- Peter Libby on Lipoprotein(a) Reduction in Persons With Cardiovascular Disease
- 2019 Top Stories in Cardiology: The COLCOT Study
- Low-Dose Colchicine Improves Outcomes After Myocardial Infarction
- Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing PCI
- Obesity and Cardiovascular Disease in Teenagers
- Improved CV Health From New Diabetes Medications: Implications for Cardiologists